UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1

Journal of clinical immunology, 2013-10, Vol.33 (7), p.1192-1203

2013

Volltextzugriff (PDF)

Specificity of human anti‐variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor‐α receptor 1

Clinical and experimental immunology, 2015-11, Vol.182 (2), p.139-148

2015

Volltextzugriff (PDF)

Specificity of human anti-variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-[alpha] receptor 1

Clinical and experimental immunology, 2015-11, Vol.182 (2), p.139

2015

Volltextzugriff (PDF)

Autoantibodies to Variable Heavy (V^sub H^) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a V^sub H^ Domain Antibody Antagonist of TNF-[alpha] Receptor 1

Journal of clinical immunology, 2013-10, Vol.33 (7), p.1192

2013

Volltextzugriff (PDF)

Specificity of human anti-variable heavy (V sub(H)) chain autoantibodies and impact on the design and clinical testing of a V sub(H) domain antibody antagonist of tumour necrosis factor- alpha receptor 1

Clinical and experimental immunology, 2015-11, Vol.182 (2), p.139-148

2015

Volltextzugriff (PDF)

Autoantibodies to Variable Heavy (V sub(H)) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a V sub(H) Domain Antibody Antagonist of TNF- alpha Receptor 1

Journal of clinical immunology, 2013-10, Vol.33 (7), p.1192-1203

2013

Volltextzugriff (PDF)

Emerging therapeutic targets in psoriasis

Current opinion in pharmacology, 2004-06, Vol.4 (3), p.306-310

2004

Volltextzugriff (PDF)

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Critical care (London, England), 2017-09, Vol.21 (1), p.234-234, Article 234

2017

Volltextzugriff (PDF)

Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study

Critical care (London, England), 2019-12, Vol.23 (1), p.400-400, Article 400

2019

Volltextzugriff (PDF)

Sodium Amide Induced Cyclization of 2-Iodoprop-2-enylamines: Application to the Synthesis of 1-Aryl-2-methyleneaziridines

Synlett, 2015-06, Vol.26 (10), p.1371-1374

2015

Volltextzugriff (PDF)

Inhibition of TNF Receptor p55 By a Domain Antibody Attenuates the Initial Phase of Acid-Induced Lung Injury in Mice

Frontiers in immunology, 2017-02, Vol.8, p.128-128

2017

Volltextzugriff (PDF)

Selective inhibition of intra-alveolar p55 TNF receptor attenuates ventilator-induced lung injury

Thorax, 2012-03, Vol.67 (3), p.244-251

2012

Volltextzugriff (PDF)

The authors reply

Critical care medicine, 2016-06, Vol.44 (6), p.e454-e455

2016

Volltextzugriff (PDF)

A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome

Critical care medicine, 2015-09, Vol.43 (9), p.1859-1869

2015

Volltextzugriff (PDF)

Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury

Thorax, 2018-08, Vol.73 (8), p.723-730

2018

Volltextzugriff (PDF)

804 Anti-tumor effect of a novel Vβ TCR-targeting bifunctional agent in combination with anti-PD1 in checkpoint refractory murine lung cancer models

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A902-A902

2023

Volltextzugriff (PDF)

A nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury: A randomised, placebo-controlled pilot study

European journal of anaesthesiology, 2020-11, Vol.37 (11), p.1014-1024

2020

Volltextzugriff (PDF)

Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS2671-TPS2671

2023

Volltextzugriff (PDF)

STAR0602, a novel TCR agonist antibody, demonstrates potent antitumor activity in refractory solid tumor models through the expansion of a novel, polyclonal effector memory T cell subset

European journal of cancer (1990), 2022-10, Vol.174, p.S5-S5

2022

Volltextzugriff (PDF)

A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity

Science translational medicine, 2023-11, Vol.15 (724), p.eadi0258

2023

Volltextzugriff (PDF)

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

Pulmonary circulation, 2022-01, Vol.12 (1), p.e12024-n/a

2022

Volltextzugriff (PDF)

Abstract 2357: T cell receptor beta chain-directed Tri-specific antibody molecules retarget V-beta T cell subsets to tumors to promote potent and durable antitumor activity

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.2357-2357

2024

Volltextzugriff (PDF)

Abstract LB338: A novel class of T cell-activators targeting germline encoded TCRβ chains promotes antitumor activity in PD1-refractory models through expansion of a clonally enriched effector memory T cell subset

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB338-LB338

2023

Volltextzugriff (PDF)

Abstract 1425: Epigenetic modulation synergizes with a novel TCR β chain directed antibody-fusion molecule to suppress checkpoint-refractory tumors irrespective of MHC I status

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.1425-1425

2024

Volltextzugriff (PDF)

Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells

Cytokine (Philadelphia, Pa.), 2007-09, Vol.39 (3), p.184-191

2007

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Englisch
(49)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(13)
Humans
(12)
Animals
(6)
Male
(5)
Ventilators
(5)
Adult
(4)
Cytokines
(4)
Female
(4)
General & Internal Medicine
(4)
Middle Aged
(4)
Technology
(4)
Tumor Necrosis Factor-Tnf
(4)
Acute Respiratory Distress Syndrome
(3)
Aged
(3)
Antibodies, Monoclonal - Administration & Dosage
(3)
Chemistry
(3)
Critical Care
(3)
Critical Care Medicine
(3)
Dose-Response Relationship, Drug
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1

Specificity of human anti‐variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor‐α receptor 1

Specificity of human anti-variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-[alpha] receptor 1

Autoantibodies to Variable Heavy (V^sub H^) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a V^sub H^ Domain Antibody Antagonist of TNF-[alpha] Receptor 1

Specificity of human anti-variable heavy (V sub(H)) chain autoantibodies and impact on the design and clinical testing of a V sub(H) domain antibody antagonist of tumour necrosis factor- alpha receptor 1

Autoantibodies to Variable Heavy (V sub(H)) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a V sub(H) Domain Antibody Antagonist of TNF- alpha Receptor 1

Emerging therapeutic targets in psoriasis

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study

Sodium Amide Induced Cyclization of 2-Iodoprop-2-enylamines: Application to the Synthesis of 1-Aryl-2-methyleneaziridines

Inhibition of TNF Receptor p55 By a Domain Antibody Attenuates the Initial Phase of Acid-Induced Lung Injury in Mice

Selective inhibition of intra-alveolar p55 TNF receptor attenuates ventilator-induced lung injury

The authors reply

A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome

Novel anti-tumour necrosis factor receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in experimental acute lung injury

804 Anti-tumor effect of a novel Vβ TCR-targeting bifunctional agent in combination with anti-PD1 in checkpoint refractory murine lung cancer models

A nebulised antitumour necrosis factor receptor-1 domain antibody in patients at risk of postoperative lung injury: A randomised, placebo-controlled pilot study

Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment

STAR0602, a novel TCR agonist antibody, demonstrates potent antitumor activity in refractory solid tumor models through the expansion of a novel, polyclonal effector memory T cell subset

A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

Abstract 2357: T cell receptor beta chain-directed Tri-specific antibody molecules retarget V-beta T cell subsets to tumors to promote potent and durable antitumor activity

Abstract LB338: A novel class of T cell-activators targeting germline encoded TCRβ chains promotes antitumor activity in PD1-refractory models through expansion of a clonally enriched effector memory T cell subset

Abstract 1425: Epigenetic modulation synergizes with a novel TCR β chain directed antibody-fusion molecule to suppress checkpoint-refractory tumors irrespective of MHC I status

Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells

Suchergebnisse filtern